GSK and ViiV Healthcare Sign an Exclusive License Agreement with NIH for its Investigational bNAb to Treat and Prevent HIV

 GSK and ViiV Healthcare Sign an Exclusive License Agreement with NIH for its Investigational bNAb to Treat and Prevent HIV

GSK and ViiV Healthcare Signs an Exclusive License Agreement with NIH for its Investigational bNAb to Prevent HIV Infection

Shots:

  • NIAID, part of NIH to receive milestones and royalties on sales of N6LS. GSK and NIH to jointly identify & develop broadly neutralizing antibodies (bNAbs) including N6LS for providing the treatment & preventative options for HIV transmission
  • ViiV to initiate P-IIa study with material manufactured by the NIAID Vaccine Research Center and will lead to evaluation of efficacy, safety, tolerability, and PK profile of N6LS in adults living with HIV
  • N6LS is an antiviral bNAb, designed to bind to a specific site (gp120) on the surface of HIV, preventing its entry into uninfected immune system cells (CD4+ T-cells), thus the HIV replication is halted, and its transmission is prevented

Click here to­ read full press release/ article | Ref: GSK | Image: ViiV Healthcare

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post